Ulteriori informazioni
The "Novel Therapeutic Targeting in Cancer: An Interdisciplinary Approach" is the twenty sixth volume of the "Interdisciplinary Cancer Research" series, publishes comprehensive volume on novel therapeutic targeting in cancer. The volume starts with a chapter on telomere, DNA damage response, and nanomedicine, as a triad for cancer treatment innovation, followed by two general chapters on precision oncology and interdisciplinary pathways for cancer treatment. Advanced targeting systems for tissue-specific drug delivery and new-generation drug delivery systems as anticancer strategies are the subjects of the following chapters. After discussion on targeting inflammatory proteins for inhibition of cell proliferation in tumor microenviroment, small RNAs, microRNAs, as well as implementing CRISPR/Cas9 and microbiota genomics are explained. Targeting glycan, lectin-based targeted drug delivery systems, proteolysis targeting chimeras, dihydrofolate reductase inhibitors, PARP, ATR, RUVBL1/2 complex, and metal-coordination complexes in cancer treatment are explained in other chapters. Finally, computational advancements and in vitro evaluation in pre-clinical anticancer drug discovery and development are discussed in the last chapter. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for those who wish to have an update on cancer therapeutic targeting.
Info autore
Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research and Technologies, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the Founder of Universal Scientific Education and Research Network (USERN). Prof. Rezaei has already been the Director of more than two hundred research projects and has designed and participated in several international collaborative projects. Prof. Rezaei is the editor, editorial assistant, or editorial board member of more than fifty international journals. He has edited more than one hundred international books, has presented more than a thousand lectures/posters in congresses/meetings, and has published more than 1,700 scientific papers in the international journals.
Riassunto
The “Novel Therapeutic Targeting in Cancer: An Interdisciplinary Approach” is the twenty sixth volume of the “Interdisciplinary Cancer Research” series, publishes comprehensive volume on novel therapeutic targeting in cancer. The volume starts with a chapter on telomere, DNA damage response, and nanomedicine, as a triad for cancer treatment innovation, followed by two general chapters on precision oncology and interdisciplinary pathways for cancer treatment. Advanced targeting systems for tissue-specific drug delivery and new-generation drug delivery systems as anticancer strategies are the subjects of the following chapters. After discussion on targeting inflammatory proteins for inhibition of cell proliferation in tumor microenviroment, small RNAs, microRNAs, as well as implementing CRISPR/Cas9 and microbiota genomics are explained. Targeting glycan, lectin-based targeted drug delivery systems, proteolysis targeting chimeras, dihydrofolate reductase inhibitors, PARP, ATR, RUVBL1/2 complex, and metal-coordination complexes in cancer treatment are explained in other chapters. Finally, computational advancements and in vitro evaluation in pre-clinical anticancer drug discovery and development are discussed in the last chapter. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for those who wish to have an update on cancer therapeutic targeting.
